All In Biotech

Drug Trial Radar · NCT06052566

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Efinopegdutide (MK-6024) in Participants With Moderate and Severe Hepatic Impairment

Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

22

Actual

Start

Nov 21, 2023

Primary completion

Dec 5, 2024

Study completion Dec 5, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.

Conditions

  • Non-alcoholic Steatohepatitis
  • Hepatic Impairment

Interventions

  • EfinopegdutideDrug

    Subcutaneous injection administered at a dose of 7 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve From Time 0 to Infinity (AUC0-inf) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
  2. Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
  3. Maximum Plasma Concentration (Cmax) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
  4. Time to Maximum Concentration (Tmax) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
  5. Apparent Terminal Half-life (t/12) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
  6. Apparent Total Clearance (CL/F) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
  7. Apparent Volume of Distribution (Vz/F) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Pharmacology of Miami ( Site 0005)

    Miami, Florida

  • Advanced Pharma CR, LLC ( Site 0001)

    Miami, Florida

  • Genesis Clinical Research, LLC ( Site 0006)

    Tampa, Florida

  • American Research Corporation ( Site 0002)

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.